Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below 200-Day Moving Average of $2.97

Shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.97 and traded as low as $2.59. Minerva Neurosciences shares last traded at $2.61, with a volume of 3,790 shares traded.

Wall Street Analysts Forecast Growth

NERV has been the topic of a number of recent analyst reports. HC Wainwright lowered their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. StockNews.com began coverage on shares of Minerva Neurosciences in a report on Saturday. They set a “sell” rating for the company.

Minerva Neurosciences Stock Up 0.8 %

The stock has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $2.92. The firm has a market cap of $18.25 million, a PE ratio of -0.58 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts expect that Minerva Neurosciences, Inc. will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.